Humacyte Funding Round

10/20/2015

Venture Equity

$150,000,000

Series B

The funding will support the upcoming global Phase III clinical trials of Humacyte's investigational human acellular vessel (HAV), HUMACYL, currently being developed to provide vascular access for patients with End Stage Renal Disease (ESRD) who require hemodialysis, a process of cleansing blood for patients whose kidneys no longer function adequately. Funding will also support the development of future pipeline products with the potential to improve treatment outcomes for patients with a variety of vascular and non-vascular diseases, such as Coronary Artery Bypass, Replacement Trachea and Esophagus, and bypass for Peripheral Arterial Disease.

Private & Independent

Medical Devices & Instruments

2525 E NC Hwy. 54
Durham, NC 27713
USA

Humacyte uses proprietary technology to grow stable, off-the-shelf human tissue replacements such as vein grafts to pre-designed clinical and commercial specifications.